Amgen dumps early-stage CD38xCD3 bispecific as 3 programs are sidelined by trial setbacks
Five years after Amgen $AMGN agreed to wager up to $1.8 billion on an alliance with Xencor that spotlighted their preclinical bispecific T cell engager program directed at CD38 and CD3 for multiple myeloma, the big biotech is walking away from the program — one of 3 that were scuttled on trial setbacks.
In a review of R&D activities for Q2 Tuesday evening, Amgen noted:
Phase 1 development of AMG 424, a CD38-CD3 XmAb antibody has been stopped, with rights reverting to Xencor.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,500+ biopharma pros reading Endpoints daily — and it's free.